切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2023, Vol. 17 ›› Issue (02) : 217 -220. doi: 10.3877/cma.j.issn.1674-3946.2023.02.026

综述

外周血非编码RNA在胰腺癌中研究进展
李泽乾1, 郝少龙1, 张博1, 纪凯伦1, 韩威1,()   
  1. 1. 101100 北京,首都医科大学附属北京潞河医院普通外科
  • 收稿日期:2022-10-09 出版日期:2023-04-26
  • 通信作者: 韩威

Research progress of peripheral blood non-coding RNA in pancreatic cancer

Zeqian Li1, Shaolong Hao1, Bo Zhang1, Kailun Ji1, Wei Han1,()   

  1. 1. Department of General Surgery, Beijing Luhe Hospital, Capital Medical University, Beijing 101100, China
  • Received:2022-10-09 Published:2023-04-26
  • Corresponding author: Wei Han
  • Supported by:
    Capital’s Funds for Health Improvement and Research(CFH-2022-2-7081); Beijing Tongzhou District Science and Technology Project(KJ2022CX016)
引用本文:

李泽乾, 郝少龙, 张博, 纪凯伦, 韩威. 外周血非编码RNA在胰腺癌中研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2023, 17(02): 217-220.

Zeqian Li, Shaolong Hao, Bo Zhang, Kailun Ji, Wei Han. Research progress of peripheral blood non-coding RNA in pancreatic cancer[J/OL]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 217-220.

胰腺癌是恶性程度高的消化系统肿瘤,随着非编码RNA在胰腺癌中的研究不断深入,发现非编码RNA具有作为诊断胰腺癌生物标志物和治疗靶点的重要潜能。外周血非编码RNA的检测更是因简便、非侵入性等优势而深受广大研究者的青睐。通过搜集近些年来外周血非编码RNA与胰腺癌的相关研究,本文将从微小RNA(miRNA)、长链非编码RNA(lncRNA)和环状RNA(circRNA)三方面对外周血非编码RNA在胰腺癌诊疗中的研究进展作一综述。

Pancreatic cancer is a digestive system tumor with a high degree of malignancy. With the deepening of research on non-coding RNA in pancreatic cancer,it has been found that non-coding RNA has important potential as biomarkers and therapeutic targets in the diagnosis of pancreatic cancer. The detection of peripheral blood non-coding RNA is favored by the majority of researchers because of its simplicity and non-invasive advantages. By collecting relevant studies on peripheral blood non-coding Rnas and pancreatic cancer in recent years,this paper reviews the research progress of peripheral blood non-coding Rnas in the diagnosis and treatment of pancreatic cancer from the perspectives of micrornas(mirnas),long-chain non-coding Rnas(lncrnas)and circrnas.

[1]
Ilic MIlic I. Epidemiology of pancreatic cancer[J]. World J Gastroenterol201622(44):9694-9705.
[2]
Vincent AHerman JSchulick R,et al. Pancreatic cancer[J]. Lancet2011378(9791):607-620.
[3]
赵建国,廖泉,赵玉沛. 胰腺癌分子标志物研究进展[J/CD]. 中华普外科手术学杂志(电子版)20137(03):224-226.
[4]
Huang JLiu JChen-Xiao K,et al. Advance in microRNA as a potential biomarker for early detection of pancreatic cancer[J]. Biomark Res20164:20.
[5]
Chandra Gupta SNandan Tripathi Y. Potential of long non-coding RNAs in cancer patients:From biomarkers to therapeutic targets[J]. Int J Cancer2017140(9):1955-1967.
[6]
谢雨婷,高军. 微小RNA在胰腺癌诊断中的研究进展[J]. 中华胰腺病杂志202222(02):148-152.
[7]
Schultz NADehlendorff CJensen BV,et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer[J]. JAMA2014311(4):392-404.
[8]
Chen JYao DChen W,et al. Serum exosomal miR-451a acts as a candidate marker for pancreatic cancer[J]. Int J Biol Markers202237(1):74-80.
[9]
Yang JXu RWang C,et al. Early screening and diagnosis strategies of pancreatic cancer:a comprehensive review[J]. Cancer Commun(Lond)202141(12):1257-1274.
[10]
Szafranska-Schwarzbacht AEAdai ATLee LS,et al. Development of a miRNA-based diagnostic assay for pancreatic ductal adenocarcinoma[J]. Expert Rev Mol Diagn201111(3):249-257.
[11]
Morimura RKomatsu SIchikawa D,et al. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer[J]. Br J Cancer2011105(11):1733-1740.
[12]
Kawaguchi TKomatsu SIchikawa D,et al. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer[J]. Br J Cancer2013108(2):361-369.
[13]
Liang LWei DMLi JJ,et al. Prognostic microRNAs and their potential molecular mechanism in pancreatic cancer:A study based on The Cancer Genome Atlas and bioinformatics investigation[J]. Mol Med Rep201817(1):939-951.
[14]
Muro KFuchs CSJang RWJ,et al. KEYNOTE-059 cohort 1:Pembrolizumab(Pembro)monotherapy in previously treated advanced gastric or gastroesophageal junction(G/GEJ)cancer in patients(Pts)with PD-L1+tumors-Asian subgroup analysis[J]. J Clinical Onc201836(4):1.
[15]
Wang PZhuang LZhang J,et al. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer,and miR-21 expression confers chemoresistance by targeting FasL[J]. Mol Oncol20137(3):334-345.
[16]
Gisel AValvano MEl Idrissi IG,et al. miRNAs for the Detection of MultiDrug Resistance:Overview and Perspectives[J]. Molecules 201419(5):5611-5623.
[17]
Jung HErtl LJanson C,et al. Inhibition of CCR2 potentiates the checkpoint inhibitor immunotherapy in pancreatic cancer[J]. Cancer Immunol Res20164(11):1123.
[18]
Lu YLu JLi X,et al. MiR-200a inhibits epithelial-mesenchymal transition of pancreatic cancer stem cell[J]. BMC Cancer201414:85.
[19]
Ma CHuang TDing YC,et al. microRNA-200c overexpression inhibits chemoresistance,invasion and colony formation of human pancreatic cancer stem cells[J]. Int J Clin Exp Pathol20158(6):6533-6539.
[20]
Singh SChitkara DKumar V,et al. miRNA profiling in pancreatic cancer and restoration of chemosensitivity[J]. Cancer Lett2013334(2):211-220.
[21]
Mittal AChitkara DBehrman SW,et al. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer[J]. Biomaterials201435(25):7077-7087.
[22]
Sicard FGayral MLulka H,et al. Targeting miR-21 for the Therapy of Pancreatic Cancer[J]. Mol Ther201321(5):986-994.
[23]
Huarte M. The emerging role of lncRNAs in cancer[J]. Nat Med201521(11):1253-1261.
[24]
Wang YLi ZZheng S,et al. Expression profile of long non-coding RNAs in pancreatic cancer and their clinical significance as biomarkers[J]. Oncotarget20156(34):35684-35698.
[25]
Li LZhang GQChen H,et al. Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer[J]. Oncotarget20167(44):71773-71781.
[26]
Lu HYang DZhang L,et al. Linc-pint inhibits early stage pancreatic ductal adenocarcinoma growth through TGF-beta pathway activation[J]. Oncol Lett201917(5):4633-4639.
[27]
Liu YFeng WLiu W,et al. Circulating lncRNA ABHD11-AS1 serves as a biomarker for early pancreatic cancer diagnosis[J]. J Cancer201910(16):3746-3756.
[28]
Lu HYe JZhang L,et al. Downregulation of LINC01638 lncRNA inhibits migration and invasion of pancreatic ductal adenocarcinoma cells by reducing TGF-beta signaling[J]. Mol Med Rep201920(5):4533-4539.
[29]
Takahashi KOta YKogure T,et al. Circulating extracellular vesicle-encapsulated HULC is a potential biomarker for human pancreatic cancer[J]. Cancer Sci2020111(1):98-111.
[30]
Pan SShen MZhou M,et al. Long noncoding RNA LINC01111 suppresses pancreatic cancer aggressiveness by regulating DUSP1 expression via microRNA-3924[J]. Cell Death Dis201910(12):883.
[31]
Li ZZhao XZhou Y,et al. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer[J]. J Transl Med201513:84.
[32]
You LWang HYang G,et al. Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207[J]. Mol Oncol201812(12):2147-2164.
[33]
Gonzalez-Duarte ABerk JLQuan D,et al. Analysis of autonomic outcomes in APOLLO,a phase Ⅲ trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis[J]. J Neurol2020267(3):703-712.
[34]
Zhen SLi X. Application of CRISPR-Cas9 for Long Noncoding RNA Genes in Cancer Research[J]. Hum Gene Ther201930(1):3-9.
[35]
Yang FLiu DYGuo JT,et al. Circular RNA circ-LDLRAD3 as a biomarker in diagnosis of pancreatic cancer[J]. World J Gastroenterol201723(47):8345-8354.
[36]
Xu YYao YGao P,et al. Upregulated circular RNA circ_0030235 predicts unfavorable prognosis in pancreatic ductal adenocarcinoma and facilitates cell progression by sponging miR-1253 and miR-1294[J]. Biochem Biophys Res Commun2019509(1):138-142.
[37]
Hao LRong WBai L,et al. Upregulated circular RNA circ_0007534 indicates an unfavorable prognosis in pancreatic ductal adenocarcinoma and regulates cell proliferation,apoptosis,and invasion by sponging miR-625 and miR-892b[J]. J Cell Biochem2019120(3):3780-3789.
[38]
Xu CYu YDing F. Microarray analysis of circular RNA expression profiles associated with gemcitabine resistance in pancreatic cancer cells[J]. Oncol Rep201840(1):395-404.
[39]
Liu YXia LDong L,et al. CircHIPK3 Promotes Gemcitabine(GEM)Resistance in Pancreatic Cancer Cells by Sponging miR-330-5p and Targets RASSF1[J]. Cancer Manag Res202012:921-929.
[1] 李国新, 陈新华. 全腹腔镜下全胃切除术食管空肠吻合的临床研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 1-4.
[2] 陈方鹏, 杨大伟, 金从稳. 腹腔镜近端胃癌切除术联合改良食管胃吻合术重建His角对术后反流性食管炎的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 15-18.
[3] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[4] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[5] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[6] 任佳, 马胜辉, 王馨, 石秀霞, 蔡淑云. 腹腔镜全胃切除、间置空肠代胃术的临床观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 31-34.
[7] 赵丽霞, 王春霞, 陈一锋, 胡东平, 张维胜, 王涛, 张洪来. 内脏型肥胖对腹腔镜直肠癌根治术后早期并发症的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 35-39.
[8] 吴晖, 佴永军, 施雪松, 魏晓为. 两种解剖入路下行直肠癌侧方淋巴结清扫的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 40-43.
[9] 周世振, 朱兴亚, 袁庆港, 刘理想, 王凯, 缪骥, 丁超, 汪灏, 管文贤. 吲哚菁绿荧光成像技术在腹腔镜直肠癌侧方淋巴结清扫中的应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 44-47.
[10] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[11] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[12] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[13] 王露, 周丽君. 全腹腔镜下远端胃大部切除不同吻合方式对胃癌患者胃功能恢复、并发症发生率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 92-95.
[14] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[15] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?